Nesterenko Vladimir Mikhailovich

Nesterenko Vladimir Mikhailovich

Biography

2018: General Director of Pharmacy Chain 36.6

From 2018 to 2020, he was the general director of PJSC Pharmacy Chain 36.6, and during this period he implemented a new anti-crisis strategy for the development of the company.

2020

G Dee Pi CEO

Since 2020, he has held the position of general director of the distribution division "36.6" - the company "Ji-Ji-Pi."

Purchase of GD Distribution Business

In mid-December 2020, the 36.6 pharmacy chain announced the sale of its distribution business. We are talking about the Ji Di Pi division, which was bought by the former CEO of the company Vladimir Nesterenko. Read more here.

2022: Withdrawal from the founders of "Ji Dee Pi"

According to the Unified State Register of Legal Entities, in October 2022, Vladimir Nesterenko resigned from the founders of Ji Di Pi LLC.

2023: CEO of Nanolek

Vladimir Nesterenko became the general director of Nanolek. Its co-founder and former leader Mikhail Nekrasov decided to leave his post and focus on scientific activities. This was reported to Zdrav.Expert by representatives of Nanolek on May 17, 2023.

"Nanolek, whose management was entrusted to me, is not only a well-formed portfolio of drugs for the treatment of socially significant diseases, providing it with sustainable growth, but also one of the best teams in the Russian pharmaceutical market. I am sure that the foundation formed over the years of the company's work will allow us to implement a development strategy taking into account new regulatory trends and changing market realities, "said Vladimir Nesterenko.

According to Nanolek, Vladimir Nesterenko has a rich managerial experience in. pharmaceutical industries He began his professional career as a anesthesiologist resuscitator, has a Ph.D medical. He held leadership positions in production, distributor companies, as well as in. pharmacy retail

At Nanolek, Vladimir Nesterenko plans to maintain and strengthen the system of partnerships with both international and Russian companies, moving towards the goal of becoming a leader in the pediatric vaccine market.

Meanwhile, Mikhail Nekrasov - one of the pioneers of the new Russian pharma, a doctor by education and general director of Nanolek from 2011 to 2023. - explained the reasons for his resignation as follows:

"I have long had a dream to engage in the development of a drug for the treatment of cancer, with the involvement of artificial intelligence. This is from the field of basic science, while in Nanolek we were engaged in applied projects with a significantly shorter time-to-market. Within the framework of real business, there is no time for scientific activity at all. In addition, I want to change the rhythm of work to a calmer one in order to pay more attention to my family and myself. I leave the company in good hands and in stable condition. "

In 2022, the Nanolek team managed to maintain the level of the previous year and practically maintain turnover, fulfill all contracts on time and withdraw all planned products, despite the rupture of supply chains and difficulties in supplies. Maintaining the stability of the business was helped by the clear focus of Nanolek on strategic projects - pediatric vaccines, the company said.